Literature DB >> 1618595

Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine.

G Frendl1.   

Abstract

IL-3 is best known as a multicolony-stimulating factor, produced by T-cells, mast cells and eosinophils. Based on its broad spectrum of hemopoietic growth factor activity, the role of IL-3 in the homeostasis of leukocytes is apparent, although the precise mechanisms of this process are yet to be determined. The fact that activated T-helper cells are one of the most potent sources of IL-3 suggests an additional role for IL-3 in the regulation of the immune response. Although the presence of IL-3 receptors on monocytes has been demonstrated, the role of IL-3 in regulating macrophage functions was not clear until recently. We have demonstrated a unique spectrum of macrophage activating properties of IL-3, distinct from that of IFN gamma, IL-4 and other CSFs. These novel macrophage activating properties of IL-3 include its capacity to directly induce the expression of Ia antigens and members of the beta 2 integrin family (e.g. CD11a/CD18[LFA-1]), as well as to contribute to the regulation of cytokine production (IL-1, IL-6 and TNF alpha). Moreover, we observed a significant synergy between IL-3 and IFN gamma in the induction of Ia and LFA-1, as well as between IL-3 and LPS in the induction of Ia and macrophage cytokines. Our data suggest that IL-3 may help control the antigen presentation (AP) capacity of macrophage via the regulation of Ia, beta 2 integrins and macrophage cytokines. It is also possible that the differential state of activation of macrophages that we demonstrated following their induction with IL-3, IFN gamma or IL-3+IFN gamma results in the development of functionally distinct AP cells. Further immunoregulatory properties of IL-3 were observed in vivo by Kimoto and colleagues when IL-3 administration led to profound enhancement of the T-cell-dependent immune response, with no changes in the antibody response to T-cell-independent antigens. Thus, in vitro and in vivo data both confer an immunoregulatory role for IL-3 in the development of the immune response, most likely via its effects on the antigen presenting cells (macrophages). This review will summarize evidence documenting a range of immunoregulatory properties of IL-3 and discuss the mechanisms of action of IL-3.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618595     DOI: 10.1016/0192-0561(92)90172-h

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  6 in total

1.  Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.

Authors:  T W Wright; R H Notter; Z Wang; A G Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice.

Authors:  R J D'Andrea; D Harrison-Findik; C M Butcher; J Finnie; P Blumbergs; P Bartley; M McCormack; K Jones; R Rowland; T J Gonda; M A Vadas
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

3.  Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice.

Authors:  C S Chiang; H C Powell; L H Gold; A Samimi; I L Campbell
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

Review 4.  Is There a Role for Hematopoietic Growth Factors During Sepsis?

Authors:  Benjamin G Chousterman; Marine Arnaud
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

5.  Interleukin 3 prevents delayed neuronal death in the hippocampal CA1 field.

Authors:  T C Wen; J Tanaka; H Peng; J Desaki; S Matsuda; N Maeda; H Fujita; K Sato; M Sakanaka
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

6.  Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine.

Authors:  Robert O Dillman; Gabriel I Nistor; Aleksandra J Poole
Journal:  Hum Vaccin Immunother       Date:  2019-11-15       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.